FDA to miss deadline on Savara's rare lung disease drug approval
Savara Inc. announced the FDA will miss its November 22 deadline to decide on its rare lung disease drug, molgramostim. The company's shares fell 16% in premarket trading. The FDA did not provide a new decision date, and Savara's application remains under review. Molgramostim is an experimental treatment for autoimmune pulmonary alveolar proteinosis, with no FDA-approved treatments currently available.
How this was made

The 30-second read
Why it matters
The FDA missing the Nov 22 decision deadline extends uncertainty around approval timing and can increase volatility in SVRA as traders reassess the probability-weighted path to a decision.
Market read
A concrete FDA deadline miss for a rare-disease drug is a direct catalyst for biotech approval-risk positioning.
What to watch
The FDA did not provide a new date, so traders should watch for subsequent FDA communications that clarify whether the delay is administrative versus tied to new data requests.
Background
Savara is seeking FDA approval for molgramostim for autoimmune pulmonary alveolar proteinosis (PAP), a rare lung condition with no FDA-approved treatments currently.
Ticker impact
Savara said the FDA will miss the Nov 22 decision deadline for molgramostim, leaving its autoimmune PAP approval under review.
Likely pressure as the market reprices the probability/timing of an FDA decision after the missed deadline.
The article reports a concrete FDA deadline miss with no replacement date, which typically weighs on biotech approval-risk sentiment.
Market effects
Highlights ongoing FDA review-timing risk for rare-disease biotechs and can pressure peer sentiment around approval calendars.
Primarily impacts US-listed biotech risk sentiment; limited direct spillover beyond the sector.
US FDA process uncertainty can affect global biotech funding and risk appetite for similar regulatory programs.
Counterpoint
A missed deadline without safety or manufacturing concerns previously flagged could still lead to approval later, so the selloff may over-discount timing risk.
Key entities
- companySavara
Drug developer seeking FDA approval for molgramostim for autoimmune PAP.
- regulatorUS FDA
Regulatory body reviewing Savara’s approval application and missing the Nov 22 deadline.
- drugmolgramostim
Experimental nebulized treatment designed to help immune cells clear lung material in autoimmune PAP.

